loader2
NRI

SUPRIYA LIFESCIENCE LTD SHARE PRICE TODAY

Company details

627.15
675.00
234.90
675.00
6M Return 108.85%
1Y Return 117.92%
Mkt Cap.(Cr) 5,206.45
Volume 648,400
Div Yield 0.13%
OI
-
OI Chg %
-
Volume 648,400

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Supriya Lifescience announced Q1FY25 results: 

  • In the first quarter of FY25, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 21.7 % YoY increase, reaching Rs 160.63 crore compared to Rs 132.02 crore in Q1 FY24.
  • EBITDA for Q1 FY25 stood at Rs 62.54 crore, with an EBITDA Margin of 38.9%, as opposed to an EBITDA of Rs 44.49 crore in Q1 FY24 with an EBITDA margin of 33.7%. This marks a growth of 40.6% YoY. 
  • The Profit After Tax (PAT) for Q1 FY25 came at Rs 44.64 crore, compared to Rs 28.51 crore in Q1 FY24.
  • The PAT Margin stood at 27.8% in Q1 FY25, compared to 21.6% in Q1 FY24.
  • The company has seen good growth across different therapeutic areas in Q1FY25
  • European markets now contribute 51% of our business revenue up from 43% in Q4FY24 and 34% in Q1FY24. 

Saloni Wagh, Managing Director, Supriya Lifescience, commenting on the results, said, “We are engaged in discussions with a diverse range of companies, from major pharmaceutical firms to innovative enterprises, to establish partnerships for supplying tailored products. The company achieved a record capital expenditure of Rs 146 crore in the last financial year while also enhancing its return on equity by 210 basis points.

We're proud to unveil our new R&D facility at Lote Parshuram and anticipate the completion of our Ambernath lab by early Q2FY25. These state-of-the-art centers will drive our next phase of growth, focusing on advanced product development, CMO/CDMO opportunities, and expanding our portfolio to meet evolving market needs. Moving forward, the company aims for significant growth with improved profitability.”

Result PDF

View Other Company Results

Supriya Lifescience Ltd shares SWOT Analysis

Strengths (14)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Company with high TTM EPS Growth
  • New 52 week high today

Weakness (1)

  • Declining Net Cash Flow : Companies not able to generate net cash

Opportunity (3)

  • Positive Breakout Second Resistance ( LTP > R2)
  • Highest Recovery from 52 Week Low
  • RSI indicating price strength

Threats (1)

  • Companies with growing costs YoY for long term projects

Resistance and support

R1 672.2
R2 697.5
R3 720.1
Pivot

649.68

S1 624.4
S2 601.8
S3 576.5
EMA SMA
574.9
508.9
454.2
399.2
576.7
483.6
433.3
379.6
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2024-08-12 488.59 658285 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Sell 2024-08-12 488.61 658285 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2024-02-08 342.21 627793 NSE
Name Category Shares
Satish Waman Wagh PROMOTER 67.64%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Supriya Lifescience Ltd Stocks COMPARISON

Financials( in Cr) Supriya Lifescience Ltd Sun Pharmaceuticals Industries Ltd Divis Laboratories Ltd Cipla Ltd Torrent Pharmaceuticals Ltd
Price 646.90 1,862.95 5,479.35 1,659.40 3,453.90
% Change 4.10 0.50 -0.35 -0.02 0.06
Mcap Cr 5,206.45 446,984.11 145,459.76 133,999.54 116,895.52
Revenue TTM Cr 570.37 48,496.85 7,845.00 25,774.09 10,727.84
Net Profit TTM Cr 119.11 9,648.44 1,600.00 4,155.31 1,656.38
PE TTM 37.09 42.18 87.15 30.15 69.90
1 Year Return 117.92 62.17 46.08 35.08 84.84
ROCE 22.05 17.20 16.41 22.27 23.21
ROE 15.73 16.13 12.15 16.58 25.38
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 815.37 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 19,496.33 55,187.18
LAST 3M 80,557.53 41,828.42
LAST 6M 186,740.44 53,284.99
LAST 12M 326,637.89 111,035.44
Supriya Lifesciences to hold AGM

Sep 14, 2024 l BSE Announcement

Supriya Lifescience Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Sep 09, 2024 l NSE Announcement

Date Action Type Ratio
Sep 15, 2023 Dividend 30
Sep 01, 2022 Dividend 30

Supriya Lifescience Ltd Information

Stock PE (TTM)
37.09
Promoter Holding
68.3%
Book Value
101.3095
ROCE
22.05%
ROE
15.73%
Description
  • The company was incorporated as Supriya Lifescience Limited on 26 March 2008 upon the conversion of M/s Supriya Chemicals,a partnership firm, into a public limited company.The company commenced operations on 01 April 2008.The company is engaged in manufacturing and export of active pharmaceutical ingredients(APIs).The company is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients,with a focus on research and development. As of 31 March 2021,the company have niche product offerings of 39 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and antiallergic.The company have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India, contributing to 45-55% and 65-70%, respectively,of the API exports from India, between Fiscal 2017 and 2020.The company is among the largest exporters of Salbutamol Sulphate from India in Fiscal 2020 in terms of volume.The company`s products are approved by various international regulatory authorities such as USFDA, EUGMP, EDQM, SFDA NMPA, ANVISA, KFDA, PMDA, TGA and Taiwan FDA. As of 31 March 2021, the company have filed 11 active DMFs with USFDA and seven active CEPs with EDQM, for API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. The company`s business operations are supported by a modern manufacturing facility located in Parshuram Lote, Maharashtra. The manufacturing facility is spread across 23,806 sq.mts, having reactor capacity of 332 KL per day.The company presently operate five cleanrooms and are setting up two new clean rooms that are expected to be commercialised in the first quarter of Fiscal 2022. The new clean rooms will add manufacturing capacity of 215 KL per day. On 31 March 2012,the company has issued and allotted 3002400 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 12:1. On 31 March 2013,the company has issued and allotted 1626302 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 1:2. On 01 October 2015,the company has issued and allotted 9757804 equity shares of Rs 10 each as bonus shares to the shareholders in the ratio of 2:1 On 26 December 2020,the company has sub-divided its face value of equity shares from Rs 10 each to Rs 2 each. During the month of December 2021,the company came out with an Rs 700-crore public issue which comprised of a fresh issue of Rs 200 crore and an offer for sale(OFS) of Rs 500 crore by the promoter Satish Waman Wagh.The IPO shares were allotted at the price of Rs 274 per share including a premium of Rs 272 per share.The allotted shares were listed on the BSE Ltd and National Stock Exchange of India Ltd(NSE) on 28 December 2021.

Registered Address

207/208 Udyog Bhavan, Sonawala Road Goregaon (East), Mumbai, Maharashtra, 400063

Tel : 91-22-40332727
Email : cs:supriyalifescience.com
Website : http://www.supriyalifescience.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 543434
NSE Code : SUPRIYA
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE07RO01027

FAQ’s on Supriya Lifescience Ltd Shares

You can buy Supriya Lifescience Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Supriya Lifescience Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Sep 16, 2024 04:10 PM the closing price of Supriya Lifescience Ltd was Rs.646.90.

The latest PE ratio of Supriya Lifescience Ltd as of Sep 16, 2024 04:10 PM is 37.09

The latest PB ratio of Supriya Lifescience Ltd as of Sep 16, 2024 04:10 PM is 0.16

The 52-week high of Supriya Lifescience Ltd share price is Rs. 675.00 while the 52-week low is Rs. 234.90

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Sep 16, 2024 04:10 PM, the market cap of Supriya Lifescience Ltd stood at Rs. 5,206.45 Cr.

Download App

Download Our App

Play Store App Store
market app